Should I buy or sell KalVista Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KALV shares. View KALV analyst ratings or view top-rated stocks .

What is KalVista Pharmaceuticals' stock price target for 2024?

3 Wall Street analysts have issued twelve-month target prices for KalVista Pharmaceuticals' stock. Their KALV share price targets range from $20.00 to $35.00. On average, they predict the company's stock price to reach $26.33 in the next year. This suggests a possible upside of 124.3% from the stock's current price. View analysts price targets for KALV or view top-rated stocks among Wall Street analysts .

How have KALV shares performed in 2024?

KalVista Pharmaceuticals' stock was trading at $12.25 at the beginning of 2024. Since then, KALV stock has decreased by 4.2% and is now trading at $11.74. View the best growth stocks for 2024 here .

Are investors shorting KalVista Pharmaceuticals?

KalVista Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,520,000 shares, an increase of 12.2% from the March 15th total of 4,920,000 shares. Based on an average daily trading volume, of 809,700 shares, the short-interest ratio is presently 6.8 days. View KalVista Pharmaceuticals' Short Interest .

When is KalVista Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, July 5th 2024. View our KALV earnings forecast .

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) announced its earnings results on Monday, March, 11th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.09.

What other stocks do shareholders of KalVista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX) , Sorrento Therapeutics (SRNE) , Cara Therapeutics (CARA) , SCYNEXIS (SCYX) , TG Therapeutics (TGTX) , VBI Vaccines (VBIV) , Aldeyra Therapeutics (ALDX) , Catalyst Pharmaceuticals (CPRX) , Corbus Pharmaceuticals (CRBP) and Pfizer (PFE) .

How do I buy shares of KalVista Pharmaceuticals?

Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KALV

KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free KALV Stock Alerts

$11.74

-0.15 (-1.26%)

(As of 04/15/2024 ET)

Compare

Today's Range: $11.50
▼
$12.01
50-Day Range: $11.04
▼
$16.04
52-Week Range: $7.21
▼
$16.88

Volume: 313,460 shs
Average Volume: 765,791 shs
Market Capitalization: $495.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $26.33

Get KalVista Pharmaceuticals alerts:

KalVista Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 124.3% Upside
$26.33 Price Target
Short Interest: Bearish
13.08% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.79
Upright™ Environmental Score
News Sentiment: 0.46
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$3.55 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($3.05) to ($2.53) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.78 out of 5 stars

Medical Sector

230th out of 929 stocks

Pharmaceutical Preparations Industry

94th out of 422 stocks

3.5

Analyst's Opinion

Consensus Rating
KalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
KalVista Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
13.08% of the outstanding shares of KalVista Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in KalVista Pharmaceuticals has recently increased by 12.20%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
KalVista Pharmaceuticals does not currently pay a dividend.
Dividend Growth
KalVista Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
KalVista Pharmaceuticals has received a 72.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for KalVista Pharmaceuticals is -0.79.

1.9

News and Social Media Coverage

News Sentiment
KalVista Pharmaceuticals has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for KalVista Pharmaceuticals this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 2 people have added KalVista Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, KalVista Pharmaceuticals insiders have bought 231.91% more of their company's stock than they have sold. Specifically, they have bought $3,554,466.00 in company stock and sold $1,070,918.00 in company stock.
Percentage Held by Insiders
12.30% of the stock of KalVista Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.05) to ($2.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of KalVista Pharmaceuticals is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of KalVista Pharmaceuticals is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
KalVista Pharmaceuticals has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About KalVista Pharmaceuticals Stock (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

KALV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KALV Stock News Headlines

April 16, 2024 | americanbankingnews.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update

April 13, 2024 | americanbankingnews.com

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Reaffirmed by Needham & Company LLC

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

April 11, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)

April 3, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)

April 3, 2024 | businesswire.com

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

April 2, 2024 | businesswire.com

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 18, 2024 | finance.yahoo.com

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 12, 2024 | markets.businessinsider.com

Buy Rating on KalVista Pharmaceuticals Backed by Sebetralstat’s Breakthrough in HAE Treatment

March 12, 2024 | finance.yahoo.com

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

March 11, 2024 | markets.businessinsider.com

Buy Rating Reinforced by Strategic CEO Appointment and Promising Drug Development at KalVista Pharmaceuticals

March 11, 2024 | businesswire.com

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

March 8, 2024 | finanznachrichten.de

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

March 8, 2024 | businesswire.com

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

March 7, 2024 | marketwatch.com

KalVista Pharmaceuticals Stock Falls After CEO Resigns

March 7, 2024 | markets.businessinsider.com

KalVista Stock Drops After Announcement Of Resignation Of CEO Andrew Crockett

March 7, 2024 | marketwatch.com

KalVista Pharmaceuticals Names Benjamin Palleiko Chief Executive, Director

March 7, 2024 | businesswire.com

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

March 6, 2024 | businesswire.com

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference

March 4, 2024 | businesswire.com

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 28, 2024 | investing.com

KalVista reports high efficacy for HAE drug in phase 3 trial

February 27, 2024 | finance.yahoo.com

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 27, 2024 | businesswire.com

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 26, 2024 | businesswire.com

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 25, 2024 | msn.com

KalVista Pharmaceuticals (KALV) Price Target Increased by 51.92% to 32.23

February 20, 2024 | finance.yahoo.com

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

See More Headlines

Receive KALV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/15/2024
Fiscal Year End: 4/30/2024
Next Earnings (Estimated): 7/05/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KALV
CUSIP: N/A
CIK: 1348911
Web: www.kalvista.com
Phone: 857-999-0075
Fax: 866-553-3269
Employees: 118
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $26.33
High Stock Price Target: $35.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +124.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-92,910,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -86.06%
Return on Assets: -72.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.44
Quick Ratio: 5.44

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.71 per share
Price / Book: 2.49

Miscellaneous

Outstanding Shares: 42,190,000
Free Float: 36,999,000
Market Cap: $495.31 million
Optionable: Optionable
Beta: 0.88

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Benjamin L. Palleiko (Age 58)
CEO & Director
Comp: $707.1k
Dr. Christopher M. Yea Ph.D. (Age 60)
Chief Development Officer
Comp: $640.23k
Dr. Edward P. Feener Ph.D. (Age 64)
Chief Scientific Officer
Comp: $506k
Mr. Ryan Baker
Head of Investor Relations
Mr. Brian Krex J.D. (Age 56)
General Counsel
Jarrod Aldom
Vice President of Corporate Communications
Ms. Rachel M. Morten
Senior Vice President of Regulatory Affairs & QA
Dr. Michael D. Smith Pharm.D. (Age 44)
Senior Vice President of Development
Dr. Paul K. Audhya M.B.A. (Age 51)
M.D., Chief Medical Officer
Ms. Nicole Sweeny (Age 48)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KALV Stock Analysis - Frequently Asked Questions

Should I buy or sell KalVista Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KALV shares.
View KALV analyst ratings or view top-rated stocks.
What is KalVista Pharmaceuticals' stock price target for 2024?: 3 Wall Street analysts have issued twelve-month target prices for KalVista Pharmaceuticals' stock. Their KALV share price targets range from $20.00 to $35.00. On average, they predict the company's stock price to reach $26.33 in the next year. This suggests a possible upside of 124.3% from the stock's current price.
View analysts price targets for KALV or view top-rated stocks among Wall Street analysts.
How have KALV shares performed in 2024?: KalVista Pharmaceuticals' stock was trading at $12.25 at the beginning of 2024. Since then, KALV stock has decreased by 4.2% and is now trading at $11.74.
View the best growth stocks for 2024 here.
Are investors shorting KalVista Pharmaceuticals?: KalVista Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,520,000 shares, an increase of 12.2% from the March 15th total of 4,920,000 shares. Based on an average daily trading volume, of 809,700 shares, the short-interest ratio is presently 6.8 days.
View KalVista Pharmaceuticals' Short Interest.

When is KalVista Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, July 5th 2024.
View our KALV earnings forecast.
How were KalVista Pharmaceuticals' earnings last quarter?: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) announced its earnings results on Monday, March, 11th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.09.
What other stocks do shareholders of KalVista Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).
How do I buy shares of KalVista Pharmaceuticals?: Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KALV) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial